Read Gene SA
WSE:RDG
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| PL |
R
|
Read Gene SA
WSE:RDG
|
64.4m PLN |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
407.9B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
178.6B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.4B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
70.5B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR |
Loading...
|
Market Distribution
| Min | -535 500% |
| 30th Percentile | 18.1% |
| Median | 30.2% |
| 70th Percentile | 55.9% |
| Max | 807.1% |
Other Profitability Ratios
Read Gene SA
Glance View
Read-Gene SA engages in the medical research and testing. The company is headquartered in Szczecin, Woj. Zachodniopomorskie. The company went IPO on 2009-02-12. The company is focused on technologies which aim is to detect, prevent and treat malignant tumors. The firm specializes in three fields: chemoprevention, clinical trials and genetic testing. The company offers breast cancer, colon cancer and prostate cancer tests, as well as, medical consultancy, DNA tests and supplements. The firm operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o. Its major shareholder is GEN-PAT-MED Sp. z o.o.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Read Gene SA is 93.6%, which is above its 3-year median of 91.1%.
Over the last 3 years, Read Gene SA’s Gross Margin has increased from 85.4% to 93.6%. During this period, it reached a low of 84.9% on Mar 31, 2023 and a high of 93.8% on Jun 30, 2025.
